|
Vinflunine (VFL) in patients (pts) with metastatic transitional cell carcinoma of the urothelial tract (mTCCU): Clinical outcome and prognostic factors in a nationwide, real-life setting (MOVIE trial). |
| |
|
Consulting or Advisory Role - Lilly; Novartis; Pfizer; Roche/Genentech |
Research Funding - Amgen/Dompé (Inst) |
Travel, Accommodations, Expenses - Amgen; Roche/Genentech |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
Consulting or Advisory Role - Astellas Pharma; Novartis |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
Honoraria - Celgene; Novartis; Roche/Genentech |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |